Simvastatin has been shown to markedly inhibit tumor angiogenesis in human colorectal cancer and breast cancer by reducing the levels of VEGF and hypoxia-inducible factor-1α(HIF-1α) [49, 50]. Here, VEGFA is linked to breast cancer.